| Bioactivity | Tirzepatide hydrochloride (LY3298176 hydrochloride) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes[1]. | ||||||
| Name | Tirzepatide hydrochloride | ||||||
| Shortening | Y-{Aib}-EGTFTSDYSI-{Aib}-LDKIAQ-{diacid-gamma-Glu-(AEEA)2-Lys}-AFVQWLIAGGPSSGAPPPS-NH2 | ||||||
| Formula | ClH | ||||||
| Molar Mass | 4849.91 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
Tirzepatide hydrochloride
CAS: F: ClH W: 4849.91
Tirzepatide hydrochloride (LY3298176 hydrochloride) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glu
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.